Key result
Antipsychotic use in schizophrenia is linked to higher blood pressure, BMI, and waist-to-height ratio.
Why the study?
This study was conducted to assess the correlation between antipsychotic drug use, psychological distress, and cardiovascular risk factors among patients with schizophrenia.
Does antipsychotic drug use correlate with psychological distress and cardiovascular risk factors in patients with schizophrenia?
Cross-Sectional (n=143)
Does antipsychotic drug use correlate with psychological distress and cardiovascular risk factors in patients with schizophrenia?
Antipsychotic use in patients with schizophrenia is associated with increased cardiovascular risk factors, highlighting the need for regular metabolic monitoring.
Answers are grounded in this paper and cite their sources.
Highlights need for metabolic monitoring in schizophrenia; cross-sectional data leaves causality open.
AIMS: This study aims to assess the correlation between antipsychotic drug use, psychological distress and cardiovascular risk factors among patients with schizophrenia. METHODS: A cross-sectional correlational design was used to obtain data from 143 patients with schizophrenia who were conveniently selected. Data were collected by assessing selected cardiovascular risk indicators blood pressure (BP), random blood sugar (RBS), body mass index (BMI), waist-to-height ratio (WtHR) and waist circumference (WC). A self-administered questionnaire was used to collect sociodemographic data, clinical history and the 18-item Psychological Stress Index for patients with schizophrenia. RESULTS: The use of antipsychotics was associated with increased cardiovascular risk factors including BP, BMI and WtHR. Atypical antipsychotic medications were associated with weight gain and obesity which increase the risk of diabetes and cardiovascular diseases. Age was significantly correlated with systolic BP (r = 0.31), diastolic BP (r = 0.30) and RBS (r = 0.26). Furthermore, significant correlations were found between the duration of diagnosis with systolic (r = 0.26) and diastolic (r = 0.21) BP. None of the correlations between stress and the other study variables were significant. CONCLUSION: Screening of antipsychotic side effects is needed in the early phases, and attention must be paid to the cardiovascular risk in patients with schizophrenia, particularly BP, glucose level and BMI. In addition, clinicians should be informed of this evidence to set guidelines for regular monitoring of metabolic parameters. REPORTING METHOD: STROBE guidelines were followed in this study. PATIENT OR PUBLIC CONTRIBUTION: Actively involving patients in data collection, this study ensured that their voices were heard and their experiences were central to informing the research findings. In addition, involving patients in the study would enhance the relevance and applicability of the study's conclusions to real-world contexts, promoting patient-centered care and improved health outcomes for patients with schizophrenia.
No takes yet. Share an insight, caveat, or question.
Al‐Dwaikat et al. (2024) conducted a cross-sectional in Schizophrenia (n=143). Antipsychotic medications was evaluated on Correlation between antipsychotic drug use, psychological distress and cardiovascular risk factors. Antipsychotic use in patients with schizophrenia was associated with increased cardiovascular risk factors including blood pressure, BMI, and waist-to-height ratio.
Synapse has enriched 10 related papers. Consider them for comparative context: